New Triple-Threat treatment tested for tough rectal cancers
NCT ID NCT07214142
Summary
This study is testing a three-part treatment given before surgery for patients with locally advanced rectal cancer that has a high risk of coming back. The treatment combines chemotherapy, radiation, and an immunotherapy drug (a PD-1 inhibitor) to try to shrink the tumor as much as possible. The main goal is to see if this approach leads to no detectable cancer cells being found in the removed tissue after surgery.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECTAL CANCER PATIENTS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.